Tag: BRAF V600

NHS green light for Novartis skin cancer combo

by Selina McKee | Oct 18, 2018 | News | 0

The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.

Breakthrough badge for Novartis’ skin cancer combo

by Selina McKee | Oct 24, 2017 | News | 0

A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.